A carregar...
Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19
A SARS-CoV receptor-binding domain (RBD) recombinant protein was developed and manufactured under current good manufacturing practices in 2016. The protein, known as RBD219-N1 when formulated on Alhydrogel®, induced high-level neutralizing antibodies and protective immunity with minimal immunopathol...
Na minha lista:
| Publicado no: | Hum Vaccin Immunother |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7482854/ https://ncbi.nlm.nih.gov/pubmed/32298218 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2020.1740560 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|